March 29th 2023
Investigators are assessing tirabrutinib, which received orphan drug designation from the FDA, as a treatment for patients with relapsed or refractory primary central nervous system lymphoma in the phase 2 PROSPECT study.
Allele-Specific DNA Methylation Mapping Reveals Possible Regulatory Sequence Polymorphisms
July 9th 2020Researchers found that dense allele-specific DNA methylation (ASM) mapping in normal samples plus cancer samples reveals possible candidate regulatory sequence polymorphisms (rSNPS) that are difficult to find by other approaches.
FDA Grants Priority Review to Pembrolizumab Monotherapy for Classical Hodgkin Lymphoma
July 9th 2020The FDA accepted and granted priority review to a supplemental biologics license application for pembrolizumab as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
FDA Lifts Partial Clinical Hold on Pivotal Phase 2 Trial of Camidanlumab Tesirine
July 6th 2020The FDA lifted the partial clinical hold on the on the pivotal phase 2 trial of camidanlumab tesirine (Cami) – designed to evaluate the antibody drug conjugate in patients with relapsed or refractory Hodgkin lymphoma.
Continued Treatment with SGX301 in Patients with CTCL Increases Response Rates
May 10th 2020SGX301 is being evaluated for the treatment of patients with early-stage cutaneous T-cell lymphoma in the pivotal phase III FLASH study, which demonstrated that continued treatment twice weekly for 12 weeks increased the positive response rate.
Early Results from the Phase Ia/b Dose Escalation Trial of CG-806 in CLL/SLL and NHL
April 28th 2020The ongoing trial is treating patients with relapsed or refractory CLL/SLL or NHL who failed or were intolerant to 2 or more lines of established therapy, or for whom no other treatment options are available.
ILROG Recommends Alternative Radiation Treatment Schemes in Blood Cancer During COVID-19 Pandemic
April 21st 2020The International Lymphoma Radiation Oncology Group laid out a set of emergency recommendations for alternative radiation treatment schemes for treating patients with hematologic malignancies during the COVID-19 pandemic.
Economic Evaluation of CAR T-Cell Therapies by Site Care for Large B-Cell Lymphomas
April 16th 2020Researchers found that the potential availability of CAR T-cell therapies for large B-cell lymphomas with lower adverse event rates that are suitable for outpatient administration may reduce the total costs of care.
AstraZeneca Announces CALAVI Trial to Examine Acalabrutinib for Patients with COVID-19
April 15th 2020AstraZeneca announced it will be conducting a global clinical trial, CALAVI, to examine the impact of adding acalabrutinib to best supportive care for patients who are severely ill with the COVID-19 infection.
Initial Ibrutinib Dose and Its Modification Do Not Affect Survival in Patients with CLL
April 6th 2020Researchers found that in patients with chronic lymphocytic leukemia receiving commercial ibrutinib, initial dose and dose modification during therapy did not appear to impact event-free survival or overall survival.
AYAs with Certain Cancer Types Saw Improvements in 5-Year Mortality Rates
March 11th 2020A study showed that adolescents and young adults with certain types of cancers saw significant improvements in their 5-year mortality rates, while other cancer types saw little to no significant improvement among the same demographic group.